Prospective bleeding study in Glanzmann's thrombasthenia

Not Applicable

Completed

• Conditions: Glanzmann's thrombasthenia; Haematological Disorders

• Registration Number: ISRCTN15050281
• Lead Sponsor: Hemab Therapeutics

Brief Summary

2023 Results article in https://doi.org/10.1182/blood-2023-187558 (added 15/04/2024)

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-09-01
• Study Start: 2023-09-28
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Each participant must meet all of the following inclusion criteria to be eligible for enrollment in the study:
1. Participant has signed the informed consent form
2. =16 years of age
3. Participant has confirmed GT (documented diagnosis on patient held registry document or clinical record)
4. Participant has sufficient English language skills to complete the consent process, electronic questionnaires, and diary

Exclusion Criteria

Each participant must not meet any of the following exclusion criteria to be eligible for enrolment in the study:
1. Participant is currently pregnant
2. Participant has a cancer diagnosis (excluding benign or localized disease eg. basal cell carcinoma of the skin) and is currently undergoing systemic treatment
3. Participant has renal impairment currently requiring renal replacement therapy
4. Participant has liver disease currently requiring treatment
5. Participant has heart disease currently requiring treatment
6. Participant is receiving current treatment with anticoagulation or anti-platelet therapies

Study & Design

• Study Type: Observational
• Study Design: Not specified